No Data
No Data
Oppenheimer Starts ArriVent BioPharma at Outperform
IPO Roundup: Lineage, OneStream Software, and More
Express News | Arrivent Biopharma Inc : Oppenheimer Initiates Coverage With Outperform Rating; Target Price $35
Oppenheimer Initiates ArriVent BioPharma(AVBP.US) With Buy Rating, Announces Target Price $35
Oppenheimer analyst Jeff Jones initiates coverage on $ArriVent BioPharma(AVBP.US)$ with a buy rating, and sets the target price at $35.According to TipRanks data, the analyst has a success rate of 36.
H.C. Wainwright Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $25
H.C. Wainwright analyst Robert Burns maintains $ArriVent BioPharma(AVBP.US)$ with a buy rating, and maintains the target price at $25.According to TipRanks data, the analyst has a success rate of 24.0
ArriVent, Alphamab Unit to Collaborate on Antibody Drug Conjugates For Cancer Treatment
No Data